[go: up one dir, main page]

WO1995006727A3 - Utilisations de la glycoproteine de myeline d'oligodendrocytes et de portions peptidiques derivees de celle-ci dans des protocoles ayant trait a des maladies auto-immunes - Google Patents

Utilisations de la glycoproteine de myeline d'oligodendrocytes et de portions peptidiques derivees de celle-ci dans des protocoles ayant trait a des maladies auto-immunes Download PDF

Info

Publication number
WO1995006727A3
WO1995006727A3 PCT/US1994/010257 US9410257W WO9506727A3 WO 1995006727 A3 WO1995006727 A3 WO 1995006727A3 US 9410257 W US9410257 W US 9410257W WO 9506727 A3 WO9506727 A3 WO 9506727A3
Authority
WO
WIPO (PCT)
Prior art keywords
mog
autoimmune disease
autoimmune diseases
myelin oligodendrocyte
oligodendrocyte glycoprotein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1994/010257
Other languages
English (en)
Other versions
WO1995006727A2 (fr
Inventor
Brigitte Devaux
Jonathan B Rothbard
Dawn Smilek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immulogic Pharmaceutical Corp
Original Assignee
Immulogic Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immulogic Pharmaceutical Corp filed Critical Immulogic Pharmaceutical Corp
Priority to NZ273813A priority Critical patent/NZ273813A/en
Priority to JP7508328A priority patent/JPH09502346A/ja
Priority to AU77258/94A priority patent/AU7725894A/en
Priority to FI961000A priority patent/FI961000L/fi
Priority to KR1019960701093A priority patent/KR960705038A/ko
Priority to EP94928084A priority patent/EP0716696A1/fr
Publication of WO1995006727A2 publication Critical patent/WO1995006727A2/fr
Publication of WO1995006727A3 publication Critical patent/WO1995006727A3/fr
Priority to NO960858A priority patent/NO960858L/no
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)

Abstract

La présente invention concerne une molécule d'acide nucléique ayant une séquence de nucléotides codant pour la glycoprotéine humaine de myéline d'oligodendrocytes, qui est un auto-antigène lié aux maladies démyélisantes auto-immunes. La présente invention concerne également une glycoprotéine humaine de myéline d'oligodendrocytes ou des fragments antigéniques, produits par recombinaison. Les fragments antigéniques de la glycoprotéine de myéline d'oligodendrocytes qui peuvent être préparés par synthèse, représentent des épitopes de cellules T de la glycoprotéine humaine de myéline d'oligodendrocytes. La glycoprotéine humaine de myéline d'oligodendrocytes et les fragments de celle-ci sont utiles pour diagnostiquer et traiter des maladies auto-immunes. On décrit en outre des méthodes de dépistage et la mise au point de thérapies utiles pour le traitement de maladies auto-immunes.
PCT/US1994/010257 1993-09-03 1994-09-01 Utilisations de la glycoproteine de myeline d'oligodendrocytes et de portions peptidiques derivees de celle-ci dans des protocoles ayant trait a des maladies auto-immunes Ceased WO1995006727A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
NZ273813A NZ273813A (en) 1993-09-03 1994-09-01 Myelin oligodendrocyte glycoprotein autoantigen
JP7508328A JPH09502346A (ja) 1993-09-03 1994-09-01 自己免疫疾患に関連するプロトコールにおけるミエリン希突起神経膠細胞糖蛋白質およびそのペプチド部分の使用
AU77258/94A AU7725894A (en) 1993-09-03 1994-09-01 Uses of myelin oligodendrocyte glycoprotein and peptide portions thereof in protocols related to autoimmune disease
FI961000A FI961000L (fi) 1993-09-03 1994-09-01 Myeliinioligodendrosyyttiglykoproteiinin ja tämän peptidiosien käyttömuotoja autoimmuunisairauksiin liittyvissä menetelmissä
KR1019960701093A KR960705038A (ko) 1993-09-03 1994-09-01 자기 면역 질환에 관련된 프로토콜에서 미엘린 올리고덴드로시트 당 단백질 및 그의 펩타이드 부분들의 용도(users of myelin oligodendrocyte glycoprotein and peptide portions thereof in protocols related to autoimmune desease)
EP94928084A EP0716696A1 (fr) 1993-09-03 1994-09-01 Utilisations de la glycoproteine de myeline d'oligodendrocytes et de portions peptidiques derivees de celle-ci dans des protocoles ayant trait a des maladies auto-immunes
NO960858A NO960858L (no) 1993-09-03 1996-03-01 Anvendelser av myelin - oligodendrocyt-glykoprotein og peptid-deler derav i metoder i forbindelse med autoimmunsykdom

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11682493A 1993-09-03 1993-09-03
US08/116,824 1993-09-03

Publications (2)

Publication Number Publication Date
WO1995006727A2 WO1995006727A2 (fr) 1995-03-09
WO1995006727A3 true WO1995006727A3 (fr) 1995-04-13

Family

ID=22369451

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/010257 Ceased WO1995006727A2 (fr) 1993-09-03 1994-09-01 Utilisations de la glycoproteine de myeline d'oligodendrocytes et de portions peptidiques derivees de celle-ci dans des protocoles ayant trait a des maladies auto-immunes

Country Status (9)

Country Link
EP (1) EP0716696A1 (fr)
JP (1) JPH09502346A (fr)
KR (1) KR960705038A (fr)
AU (1) AU7725894A (fr)
CA (1) CA2170901A1 (fr)
FI (1) FI961000L (fr)
NO (1) NO960858L (fr)
NZ (1) NZ273813A (fr)
WO (1) WO1995006727A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK51297A3 (en) * 1994-10-25 1998-03-04 Immulogic Pharma Corp Compositions and treatment for multiple sclerosis
KR100682350B1 (ko) * 1995-05-02 2008-11-06 알렉시온 파마슈티칼스, 인코오포레이티드 변형된미엘린단백질분자
CA2250361A1 (fr) * 1996-03-28 1997-10-02 Barbara Wallner Peptides de la glycoproteine d'oligodendrocyte de myeline et leurs utilisations
WO1998033912A1 (fr) * 1997-01-30 1998-08-06 Human Genome Sciences, Inc. PROTEINE SEMBLABLE A LA GLYCOPROTEINE D'OLIGODENDROCYTE DE MYELINE (MOGp) ET PROCEDES D'UTILISATION
SE9703287D0 (sv) * 1997-09-11 1997-09-11 Astra Ab Peptides
EP1029049A2 (fr) * 1997-11-07 2000-08-23 Biogen, Inc. Bmog, nouvelle proteine de la famille des glycoproteines de myeline-oligodendrocyte, et son utilisation a des fins immunomodulatrices
JP2002523472A (ja) * 1998-08-26 2002-07-30 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 自己抗体抑制剤
CN1301756A (zh) * 1999-12-29 2001-07-04 复旦大学 一种新的多肽——髓磷脂p0蛋白14和编码这种多肽的多核苷酸
CN1352087A (zh) * 2000-11-02 2002-06-05 上海博德基因开发有限公司 一种新的多肽——人糖蛋白42和编码这种多肽的多核苷酸
WO2007008933A2 (fr) * 2005-07-11 2007-01-18 Carantech Biosciences, Inc. Compositions et procedes comprenant des variants d'epissage alternes complexes de genes de myeline/oligodendrocyte (mog) et anticorps diriges contre ceux-ci
CN101897964B (zh) * 2009-04-27 2013-04-10 中国农业大学 一种预防自身免疫疾病的药物
WO2013020914A1 (fr) * 2011-08-10 2013-02-14 Celares Gmbh Peptides peg-conjugués
GB201300684D0 (en) 2013-01-15 2013-02-27 Apitope Int Nv Peptide
SMT202000453T1 (it) * 2014-04-24 2020-09-10 Univ Florida Terapia genica a base di aav per la sclerosi multipla
CN118638228A (zh) * 2016-12-26 2024-09-13 协和麒麟株式会社 与髓鞘少突胶质细胞糖蛋白结合的抗体
US12297444B2 (en) 2020-04-14 2025-05-13 University Of Florida Research Foundation, Incorporated AAV-based gene therapies for treatment of autoimmune diseases
US11334352B1 (en) 2020-12-29 2022-05-17 Kpn Innovations, Llc. Systems and methods for generating an immune protocol for identifying and reversing immune disease

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DANIEL D. MIKOL ET AL.: "The oligodendrocyte-myelin glycoprotein belongs to a distinct family of proteins and contains the HNK-1 carbohydrate", THE JOURNAL OF CELL BIOLOGY, vol. 110, no. 2, February 1990 (1990-02-01), pages 471 - 479 *
N. KERLERO DE ROSBO ET AL.: "Reactivity to myelin antigens in multiple sclerosis", JOURNAL OF CLINICAL INVESTIGATION, vol. 92, no. 6, December 1993 (1993-12-01), pages 2602 - 2608 *
S. ABO ET AL.: "Preparation of highly purified human myelin oligodendrocyte glycoprotein in quantities sufficient for encephalitogenicity and immunogenicity studies", BIOCHEMISTRY AND MOLECULAR BIOLOGY INTERNATIONAL, vol. 30, no. 5, August 1993 (1993-08-01), pages 945 - 958 *

Also Published As

Publication number Publication date
NO960858D0 (no) 1996-03-01
EP0716696A1 (fr) 1996-06-19
AU7725894A (en) 1995-03-22
CA2170901A1 (fr) 1995-03-09
NZ273813A (en) 1998-05-27
NO960858L (no) 1996-03-01
WO1995006727A2 (fr) 1995-03-09
KR960705038A (ko) 1996-10-09
FI961000A7 (fi) 1996-03-04
JPH09502346A (ja) 1997-03-11
FI961000A0 (fi) 1996-03-04
FI961000L (fi) 1996-03-04

Similar Documents

Publication Publication Date Title
WO1995006727A3 (fr) Utilisations de la glycoproteine de myeline d'oligodendrocytes et de portions peptidiques derivees de celle-ci dans des protocoles ayant trait a des maladies auto-immunes
EP2311952A3 (fr) Anticorps dirigé vers MART-1 protéine et ses fragments
WO2001039796A3 (fr) Vaccin destine a la prevention et au traitement de la maladie d'alzheimer et d'autres maladies associees aux substances amyloides
EP2258383A3 (fr) Peptides antigènes dérivés de la télomérase
TW264480B (fr)
WO2002096937A3 (fr) Vaccin destine a la prevention et au traitement de la maladie d'alzheimer et d'autres maladies associees au substances amyloides
WO1995029193A3 (fr) Antigenes du melanome
WO2002081505A3 (fr) Peptide servant au diagnostic et a la therapie de la maladie d'alzheimer
WO2002006339A3 (fr) Nouvelles proteines et acides nucleiques les codant
KR960703014A (ko) Mhc 분자 hla-c-클론 10과 복합체를 형성하는 분리된 펩티드 및 그것의 사용(isolated peptides which form complexes with mhc molecule hla-c-clone 10 and uses thereof)
CA2082382A1 (fr) Proteines de surface cd44 variantes, sequences d'adn codant pour ces proteines, anticorps contre ces proteines et utilisation de ces proteines a des fins diagnostiques et therapeutiques
WO1994021675A3 (fr) Determinants antigeniques de lymphocites t de l'allergene contenu dans le pollen du ray-grass
NZ279963A (en) Human tissue inhibitor of metalloproteinase-4 (timp-4) and dna (rna) encoding polypeptide which may be derived from atcc 75946
WO2003089575A3 (fr) Anticorps se liant specifiquement au tl5
WO2002057453A3 (fr) Polypeptides et acides nucleiques codant ces derniers
WO1996028470A3 (fr) Analogues peptidiques de proteine de base de myeline utile dans le traitement de la sclerose en plaques
WO1996021734A3 (fr) Antigenes p15 et tyrosinase du melanome et leur utilisation dans des procedes diagnostiques et therapeutiques
WO2001029217A3 (fr) Polypeptides, et polynucleotides codant ces polypeptides
WO2001081578A3 (fr) Nouvelles proteines et acides nucleiques codant ces dernieres
WO1993021321A3 (fr) EPITOPES DE LYMPHOCYTES T DES PRINCIPAUX ALLERGENES D'$i(AMBROSIA ARTEMISIIFOLIA)
WO1996018646A3 (fr) Peptides de proteines de choc thermique et procedes de modulation d'une maladie auto-immune du systeme nerveux central
EP0773290A3 (fr) Protéines analogues de récepteur à LDL et gènes codant pour celles-ci
WO2002059146A3 (fr) Peptides presentant une affinite pour la proteine virale gp120, et utilisation de ces peptides
WO2001040291A3 (fr) Nouvelles proteines et acides nucleiques codant ces proteines
WO1997022694A3 (fr) Reactifs diagnostiques associes au diabete

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB HU JP KP KR KZ LK LU LV MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 273813

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2170901

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 961000

Country of ref document: FI

WWE Wipo information: entry into national phase

Ref document number: 1994928084

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1994928084

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1994928084

Country of ref document: EP